Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

SIMPLE SUMMARY: Patients with high-risk neuroblastoma who are unable to achieve a complete response to induction chemotherapy are known as primary refractory and have poor outcomes. We investigated the combination of chemotherapy (irinotecan (I) and temozolomide (T)) plus anti-GD2 immunotherapy (nax...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz, Juan Pablo, Larrosa, Cristina, Chamorro, Saray, Perez-Jaume, Sara, Simao, Margarida, Sanchez-Sierra, Nazaret, Varo, Amalia, Gorostegui, Maite, Castañeda, Alicia, Garraus, Moira, Lopez-Miralles, Sandra, Mora, Jaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571514/
https://www.ncbi.nlm.nih.gov/pubmed/37835531
http://dx.doi.org/10.3390/cancers15194837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571514/
https://www.ncbi.nlm.nih.gov/pubmed/37835531
http://dx.doi.org/10.3390/cancers15194837

Ejemplares similares